Triple-Negative Breast Cancer: Current State of the Art

Perou C.M. , Sorlie T. , Eisen M.B. , Van De Rijn M. , Jeffrey S.S. , Rees A.C. , Pollack J.R. , Ross D.T. , Johnsen H. , Akslen L.A. , Fluge O. , Pergamenschikov A. , Williams C. , Zhu S.X. , Lonning P.E. , Borresen-Dale A.L. , Brown P.O. , Botstein D. : Molecular portraits of human breast tumors. Nature, 406: 747–752, 2000.

Honeth G. , Bendahi P-O , Ringner M. , Saal L.H. , Gruvberger-Saal S.K. , Lövgren K. , Grabau D. , Fernö M. , Borg A. , Hegardt C. : The CD44+/CD24– phenotype is enriched in basal-like breast tumours. Breast Cancer Res, 10: R53, 2008.

Kreike B. , van Kouwenhove M. , Horlings H. , Weigelt B. , Peterse H. , Bartelink H. , van de Vijver M.J. : Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res, 9: R65, 2007.

Nielsen T.O. , Hsu F.D. , Jensen K. , Hsu F.D. , Jensen K. , Cheang M. , Karaca G. , Hu Z. , Hernandez-Boussard T. , Livasy C. , Cowan D. , Dressler L. , Akslen L.A. , Ragaz J. , Gown A.M. , Gilks C.B. , van de Rijn M. , Perou C.M. : Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 10: 5367–5374, 2004.

Conforti R. , Bidard F-C , Michiels S. , Boulet T. , Tomasic G. , Mathieu M.C. , Delaloge S. , Andre F. : Discrepancy between triple-negative phenotype and basal-like tumor: an immunohistochemical analysis based on 150 triple-negative breast cancers. Breast Cancer Res Treat, 106: S135, 2007.

Rakha E. , El-Sayed M. , Green A. , Lee A.H.S. , Robertson J.F. , Ellis I.O. : Prognostic markers in triple-negative breast cancer. Cancer, 109: 25–32, 2007.

Laakso M. , Tanner M. , Nilsson J. , Wiklund T. , Erikstein B. , Kellokumpu-Lehtinen P. , Malmstrom P. , Wilking N. , Bergh J. , Isola J. : Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Canc Res, 12: 4185–4191, 2006.

Dent R. , Trudeau M. , Pritchard K.I. , Hanna W.M. , Kahn H.K. , Sawka C.A. , Lickley L.A. , Rawlinson E. , Sun P. , Narod S.A. : Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 13: 4429–4434, 2007.

Bauer K. , Brown M. , Cress R.D. , Parise C.A. , Caggiano V. : Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer. Cancer, 109: 1721–1728, 2007.

Schneider B.P. , Winer E.P. , Foulkes W.D. , Garber J. , Perou C.M. , Richardson A. , Sledge G.W. , Carey L.A. : Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res, 14: 8010–8018, 2008.

Ihemelandu C.U. , Naab T.J. , Mezghebe H.M. , Makambi K.H. , Siram S.M. , Leffall L.D. Jr. , Dewitty R.L. Jr. , Frederick W.A. : Basal cell-like (triple negative) breast cancer, a predictor of distant metastases in African American women. Am J Surg, 195: 153–158, 2008.

Haffty B.G. , Yang Q. , Reiss M. , Kearney T. , Higgins S.A. , Weidhaas J. , Harris L. , Hait W. , and Toppmeyer D. : Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol, 24: 5652–5657, 2006.

Kaplan H.G. , Malmgren J.A. , Atwood M.K. : T1N0 triple negative breast cancer: adjuvant chemotherapy treatment and risk of recurrence. Breast Cancer Res Treat, 106: S149, 2007.

Amar S. , Ann M.E. , Geiger X.J. , Rebecca M.B. , Winston T. , Kyle C.E. , Beiyun C. , Boughey J.C. , Edith P.A. : Prognosis and clinical outcome of patients with node negative < or = 1 cm breast cancer. Breast Cancer Res Treat, 106: S254, 2007.

Fulford L. , Easton d , Reis-Filho J. , Sofronis A. , Gillett C.E. , Lakhani S.R. , Hanby A. : Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology, 49: 22–34, 2006.

Reis-Filho J. , Milanezi F. , Steele D. , Savage K. , Simpson P.T. , Nesland J.M. , Pereira E.M. , Lakhani S.R. , Schmitt F.C. : Metaplastic basal carcinomas are basal-like tumours. Histopathology, 49: 10–21, 2006.

Moyano J.V. , Evans J.R. , Chen F. , Lu M. , Werner M.E. , Yehiely F. , Diaz L.K. , Turbin D. , Karaca G. , Wiley E. , Nielsen T.O. , Perou C.M. , Cryns V.L. : Alpha B-crystalline is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest, 116: 261–270, 2006.

Sorlie T. , Perou C.M. , Tibshirani R. , Sorliea T. , Peroua C.M. , Tibshiranie R. , Aasf T. , Geislerg S. , Johnsenb H. , Hastiee T. , Eisenh M.B. , van de Rijni M. , Jeffreyj S.S. , Thorsenk T. , Quistl H. , Matesec J.C. , Brownm P.O. , Botsteinc D. , Lonningg P.E. , Borresen-Daleb A.L. : Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 998: 10869–10874, 2001.

Young S. , Pilarski R.T. , Donenberg T. , Shapiro C. , Hammond L.S. , Miller J. , Brooks K.A. , Cohen S. , Tenenholz B. , DeSai D. , Zandvakili I. , Royer R. , Li S. , Narod S.A. : The prevalence of BR-CA1 mutation among young women with triple negative breast cancer. BMC Cancer, 9: 86, 2009.

Turner N. , Tutt A. , Ashworth A. : Hallmarks of “BRCAness” in sporadic cancers. Nat Rev Cancer, 4: 814–819, 2004.

Kennedy R.D. , Quinn J.E. , Mullan P.B. , Johnston P.G. , Harkin D.P. : The role of BRCA1 in the cellular response to chemotherapy. J Natl Canc Inst, 96: 1659–1668, 2004.

Chakravarthy B. , Pietenpol J.A. : Combined modality management of breast cancer: development of predictive markers through proteomics. Semin Oncol, 30: 23–36, 2003.

Cleator S. , Parton M. , Dowsett M. : The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer, 9: 183–195, 2002.

Geisler S. , LønningP E. , Aas T. , Johnsen H. , Fluge O. , Haugen D.F. , Lillehaug J.R. , Akslen L.A. , Borresen-Dale A.L. : Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res, 61: 2505–12, 2001.

Gadducci A. , Cianci C. , Cosio S. , Carnino F. , Fanucchi A. , Buttitta F. , Conte P.F. , Genazzani A.R. : p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen. Anticancer Res, 20: 4793–4799, 2000.

Foulkes W.D. , Brunet J.S. , Stefansson I.M. , Straume O. , Chappuis P.O. , Bégin L.R. , Hamel N. , Goffin J.R. , Wong N. , Trudel M. , Kapusta L. , Porter P. , Akslen L.A. : The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeru-loid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res, 64: 830–835, 2004.

Finn R.S. , Dering J. , Ginther C. , Wilson C.A. , Glaspy P. , Tchekmedyian N. , Slamon D.J. : Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/‘triple-negative’ breast cancer cell lines growing in vitro. Breast Cancer Res Treat, 105: 319–326, 2007.

Huang F. , Reeves K. , Han K. , Fairchild C. , Platero S. , Wong T.W. , Lee F. , Shaw P. , Clark E. : Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res, 67: 2226–2238, 2007.

Gradishar W.J. , Krasnojon D. , Cheporov S. , Makhson A.N. , Manikhas G.M. , Clawson A. , Bhar P. : Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol, 27: 3611–3619, 2009.

Berry D.A. , Cirrincione C. , Henderson I.C. , Citron M.L. , Bud-man D.R. , Goldstein L.J. , Martino S. , Perez E.A. , Muss H.B. , Norton L. , Hudis C. , Winer E.P. : Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA, 295: 1658–1667, 2006.

Bear H.D. , Anderson S. , Brown A. , Smith R. , Mamounas E.P. , Fisher B. , Margolese R. , Theoret H. , Soran A. , Wickerham D.L. , Wolmark N. : The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol, 21: 4165–4174, 2003.

Cheang M. , Chia S.K. , Tu D. , Jiang S. , Shepherd L.E. , Pritchard K.I. , Nielsen T.O. : Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. J Clin Oncol, 27: 15s (abst 519), 2009.

Gluz O. , Nitz U.A. , Harbeck N. , Ting E. , Kates R. , Herr A. , Lindemann W. , Jackisch C. , Berdel W.E. , Kirchner H. , Metzner B. , Werner F. , Schütt G. , Frick M. , Poremba C. , Diallo-Danebrock R. : Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol, 19: 861–870, 2008.

Hannemann J , Kristel P. , van Tinteren H. , Bontenbal M. , van Hoesel Q.G. , Smit W.M. , Nooij M.A. , Voest E.E. , van der Wall E. , Hupperets P. , de Vries E.G. , Rodenhuis S. , van de Vijver M.J. : Molecular subtypes of breast cancer and amplification of topoisomerase II: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer, 95: 1334–1341, 2006.

Le Tourneau C. , Dettwiler S. , Laurence V. , Alran S. , Beuzeboc P. , Pierga J.Y. , Frenaux P. , Sigal Zafrani B. , Dieras V. , Vincent-Salomon A. : 47% pathologic complete response rate to anthracyclines-based associated with high cyclophosphamide doses neoadjuvant chemotherapy in basal-like and triple negative breast cancer patients. Breast Cancer Res Treat, 106: S169, 2007.

Carey L.A. , Dees E.C. , Sawyer L.R. , Gatti L. , Moore D.T. , Collichio F. , Ollila D.W. , Sartor C.I. , Graham M.L. , Perou M. : The triple negative paradox: primary tumor chemosensitivity of the basal-like breast cancer phenotype. Clin Cancer Res, 13: 2329–2334, 2007.

Chen J.H. , Mehta R.S. , Carpenter P.M. , Nalcioglu O. , Su M.Y. : Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy. Correspondence. J Clin Oncol, 25: 5667–5669, 2007.

Liedtke C. , Mazouni C. , Hess K.R. , Andrè F. , Tordai A. , Mejia J.A.A.M. , Hennessy B. , Green M. , Cristofanilli M. , Hortobagyi G.N. , Pusztai L. : Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol, 26: 1275–1281, 2008.

Esserman L.J. , Perou C. , Cheang M. , DeMichele A. , Carey L. , van't Veer L.J. , Gray J. , Petricoin E. , Conway K. , Hylton N. , Berry D. , I-SPY Investigators: Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). J Clin Oncol, 27: Abstract LBA515, 2009.

Rouzier R. , Perou C.M. , Symmans W.F. , Ibrahim N. , Cristofanilli M. , Anderson K. , Hess K.R. , Stec J. , Ayers M. , Wagner P. , Morandi P. , Fan C. , Rabiul I. , Ross J.S. , Hortobagyi G.N. , Pusztai L. : Breast cancer molecular subtypes respond differently to preoperatory chemotherapy. Clin Cancer Res, 11: 5678–5685, 2005.

Roche H. , Perez E. , Llombart-Cussac A. : Ixabepilone, an epothilone analog, is effective in ER-, PR-, HER2-negative (triple-negative) patients: data from neoadjuvant and metastatic breast cancer trials. Ann Oncol, 17: 256P, 2006.

Garber J.E. , Richardson A. , Harris L.N. : Neoadjuvant CDDP in triple negative breast cancer. Breast Cancer Res Treat, 100(Suppl 1): abst 3074, 2006.

Silver D.P. , Richardson A.L. , Eklund A.C. , Wang Z.C. , Szallasi Z. , Li Q. , Juul N. , Leong C-O , Calogrias D. , Buraimoh A. , Fatima A. , Gelman R.S. , Ryan P.D. , Tung N.M. , De Nicolo A. , Ganesan S. , Miron A. , Colin C. , Sgroi D.C. , Ellisen L.W. , Winer E.P. , Garber J.E. : Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol, 28: 1145–1153, 2010.

Torrisi R. , Balduzzi A. , Ghisini R. , Rocca A. , Bottiglieri L. , Giovanardi F. , Veronesi P. , Luini A. , Orlando L. , Viale G. , Goldhirsch A. , Colleoni M. : Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol, 62: 667–672, 2008.

Byrski T. , Gronwald J. , Huzarski T. , Grzybowska E. , Budryk M. , Stawicka M. , Mierzwa T. , Szwiec M. , Wi niowski R. , Siolek M. , Narod S.A. , Lubinski J. : Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Canc Res Treat, 108: 286–296, 2008.

Gronwald J. , Byrski T. , Huzarski T. , Dent R. , Bielicka V. , Zuziak D. , Wisniowski R. , Lubinski J. , Narod S. : Neoadjuvant therapy with cisplatin in BRCA1 positive breast cancer patients. J Clin Oncol, 27: 15s (abstract 502), 2009.

Sirohi B. , Arnedos M. , Popat S. , Ashley S. , Nerukar A. , Walsh G. , Johnston S. , Smith I.E. : Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol, 19: 1847–1852, 2008.

Leone J.P. , Guardiola V. , Venkatraman A. , Pegram M.D. , Welsh C. , Silva O. , Larrieux R. , Franchesci D. , Gomez C. , Hurley J. : Neoadjuvant platinum-based chemotherapy for triple negative locally advanced breast cancer: retrospective analysis of 125 patients. J Clin Oncol, 27(abst 625), 2009.

Sikov W.M. , Dizon D.S. , Strenger R. , Legare R.D. , Theall K.P. , Graves T.A. , Gass J.S. , Kennedy T.A. , Fenton M.A. : Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol, 27: 4693–4700, 2009.

Frasci G. , D'Aiuto G. , Comella P. , D'Aiuto M. , Di Bonito M. , Ruffolo P. , Iodice G. , Petrillo A. , Lastoria S. , Oliviero P. , Capasso I. , Montella M. , Siani C. , Santangelo M. , Vizioli L. , Comella G. , Southern Italy Cooperative Oncology Group, Italy: Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908. Ann Oncol, 21: 707–716, 2010.

Thomas E.S. , Gomez H.L. , Li R.K. , Chung H.C. , Fein L.E. , Chan V.F. , Jassem J. , Pivot X.B. , Klimovsky J.V. , Hurtado de Mendoza F. , Xu B. , Campone M. , Lerzo G.L. , Peck R.A. , Mukhopadhyay P. , Vahdat L.T. , Roché H.H. : Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol, 25: 5210–5217, 2007.

Rugo H.S. , Thomas E.S. , Lee R.K. , Fein L.E. , Peck R. , Verrill M. : Combination therapy with the novel epothilone B analog, ixabepilone, plus capecitabine has efficacy in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes. Breast Cancer Res Treat, 106: S270(abst 6069), 2007.

Tutt A. , Robson M. , Garber J.E. , Domchek S. , Audeh M.W. , Weitzel J.N. , Friedlander M. , Carmichael J. : Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol, 27: 18s (abst CRA501), 2009.

O'Shaughnessy J. , Osborne C. , Pippen J. , Yoffe M. , Patt D. , Monaghan G. , Rocha C. , Ossovskaya V. , Sherman B. , Bradley C. : Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol, 27: 18s (abst 3), 2009.

Tassone P. , Tagliaferri P. , Perricelli A. , Blotta S. , Quaresima B. , Martelli M.L. , Goel A. , Barbieri V. , Costanzo F. , Boland C.R. , Venuta S. : BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer, 88: 1285–1291, 2003.

Carey L.A. , Mayer E. , Marcom P.K. , Rugo H. , Liu M. , Ma C. , Rimawi M. , Storniolo A. , Forero A. , Esteva F. , Wolff A. , Ingle J. , Ferraro M. , Sawyer L. , Davidson N. , Perou C.M. , Winer E.P. : TBCRC 001: EGFR inhibition with cetuximab in metastatic triple negative (basal-like) breast cancer. Breast Cancer Res Treat, 106: S32 (abst 307), 2007.

O'Shaughnessy J. , Weckstein D.J. , Vukelja S.J. , McIntyre K. , Krekow L. , Holmes F.A. , Asmar L. , Blum J.L. : Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat, 106:S32 (abst 308), 2007.

Corkery B. , Crown J. , Clynes M. , O'Donovan N. : Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol, 20: 862–867, 2009.

Miller K. , Wang M. , Gralow J. , Dickler M. , Cobleigh M. , Perez E.A. , Shenkier T. , Cella D. , Davidson N.E. : Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med, 357: 2666–2676, 2007.

Pivot X. , Verma S. , Thomssen C. , Passos-Coelho J.L. , Latini L. , Ciruelos E. , Silva M. , von Moos R. , Chang H. , Miles D.W. : Clinical benefit of bevacizumab (BV) plus first-line docetaxel (D) in elderly patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC): AVADO study. J Clin Oncol, 27: 15s (abst 1094), 2009.

Ryan P.D. , Tung N.M. , Isakoff S.J. , Golshan M. , Richardson A. , Corben A.D. , Smith B.L. , Gelman R. , Winer E.P. , Garber J.E. : Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy. J Clin Oncol, 27: 15s (abst 551), 2009.

Burstein H.J. , Elias A.D. , Rugo H.S. , Cobleigh M.A. , Wolff A.C. , Eisenberg P.D. , Lehman M. , Adams B.J. , Bello C.L. , DePrimo S.E. , Baum C.M. , Miller K.D. : Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol, 26: 1810–1816, 2008.

Baselga J. , Segalla J.G.M. , Roché H. , del Giglio A. , Ciruelos E.M. , Cabral Filho S. , Gomez P. , Lluch A. , Llombart A. , Costa F. : 3LBA SOLTI-0701: A double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv) or metastatic (met) breast cancer (BC). Eur J Cancer Supplements, 7: 3–4, 2009.